A number of other research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 14th. Mizuho reissued a “hold” rating and set a $114.50 target price on shares of Spark Therapeutics in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating and twelve have issued a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $106.00.
Spark Therapeutics stock opened at $111.30 on Tuesday. The company has a quick ratio of 4.35, a current ratio of 4.67 and a debt-to-equity ratio of 0.35. The firm has a 50-day moving average price of $108.19 and a two-hundred day moving average price of $103.26. The firm has a market capitalization of $4.28 billion, a price-to-earnings ratio of -52.75 and a beta of 2.05. Spark Therapeutics has a 52-week low of $34.53 and a 52-week high of $114.20.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Featured Article: Holder of Record
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.